PriceTargets.com logo

Spyre Therapeutics - SYRE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $94.17
  • Forecasted Upside: 7.63%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 10 Buy Ratings
  • 2 Strong Buy Ratings
$87.49 As of 06/17/2026 05:00 PM ET
▲ +4.08 (4.89%)

This chart shows the closing price for SYRE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Spyre Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYRE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYRE

Analyst Price Target is $94.17
▲ +7.63% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Spyre Therapeutics in the last 3 months. The average price target is $94.17, with a high forecast of $115.00 and a low forecast of $53.00. The average price target represents a 7.63% upside from the last price of $87.49.

This chart shows the closing price for SYRE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 13 investment analysts is to buy stock in Spyre Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2025
  • 3 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/19/2025
  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026
  • 2 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/18/2026
  • 2 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/17/2026

Latest Recommendations

  • 2 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/16/2026WedbushReiterated RatingOutperform ➝ Outperform$100.00
6/15/2026BTIG ResearchBoost TargetBuy ➝ Buy$98.00 ➝ $112.00
6/4/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/4/2026Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy$102.00 ➝ $115.00
5/12/2026Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ Buy$102.00
5/6/2026Stifel NicolausBoost TargetBuy ➝ Buy$92.00 ➝ $107.00
5/6/2026CitigroupBoost TargetBuy ➝ Buy$64.00 ➝ $97.00
4/17/2026JonesTradingBoost TargetBuy ➝ Buy$64.00 ➝ $95.00
4/14/2026Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$50.00 ➝ $90.00
4/14/2026Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy$55.00 ➝ $88.00
4/14/2026Robert W. BairdBoost TargetOutperform ➝ Outperform$65.00 ➝ $90.00
4/13/2026Raymond James FinancialInitiated CoverageStrong-Buy$80.00
4/13/2026WedbushBoost TargetOutperform ➝ Outperform$65.00 ➝ $80.00
4/13/2026Jefferies Financial GroupBoost TargetBuy ➝ Buy$47.00 ➝ $85.00
4/13/2026Leerink PartnersBoost TargetOutperform ➝ Outperform$49.00 ➝ $106.00
4/13/2026BTIG ResearchBoost TargetBuy ➝ Buy$70.00 ➝ $98.00
3/31/2026BTIG ResearchReiterated RatingBuy ➝ Buy$70.00
3/18/2026Stifel NicolausBoost TargetBuy ➝ Buy$70.00 ➝ $92.00
3/16/2026BTIG ResearchReiterated RatingBuy ➝ Buy$70.00
2/20/2026Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$40.00 ➝ $50.00
2/20/2026BTIG ResearchReiterated RatingBuy ➝ Buy$70.00
2/19/2026Leerink PartnersUpgradeStrong-Buy
1/16/2026BTIG ResearchReiterated RatingBuy ➝ Buy$70.00
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/18/2025MizuhoUpgradeStrong-Buy
12/17/2025MizuhoInitiated CoverageOutperform$53.00
12/17/2025CitigroupInitiated CoverageBuy$64.00
12/15/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/1/2025JonesTradingUpgradeHold ➝ Buy$64.00
11/25/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/13/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/26/2025Deutsche Bank AktiengesellschaftInitiated CoverageBuy$43.00
9/16/2025BTIG ResearchReiterated RatingBuy ➝ Buy$70.00
8/6/2025WedbushReiterated RatingOutperform$65.00
5/5/2025WedbushReiterated RatingOutperform$65.00
4/8/2025Leerink PartnersUpgradeStrong-Buy
4/8/2025Leerink PartnersInitiated CoverageOutperform$45.00
3/18/2025Wolfe ResearchInitiated CoverageOutperform$27.00
2/18/2025The Goldman Sachs GroupUpgradeStrong-Buy
1/13/2025WedbushReiterated RatingOutperform$65.00
11/13/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$50.00 ➝ $65.00
11/8/2024WedbushReiterated RatingOutperform$45.00
10/25/2024GuggenheimBoost TargetBuy ➝ Buy$50.00 ➝ $65.00
9/4/2024WedbushInitiated CoverageOutperform$45.00
7/16/2024EvercoreInitiated CoverageOutperform
5/13/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$35.00 ➝ $40.00
5/10/2024BTIG ResearchBoost TargetBuy ➝ Buy$32.00 ➝ $40.00
5/2/2024Robert W. BairdInitiated CoverageOutperform$50.00
3/26/2024Stifel NicolausBoost TargetBuy ➝ Buy$36.00 ➝ $54.00
3/1/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$12.00 ➝ $35.00
12/20/2023BTIG ResearchInitiated CoverageBuy$32.00
12/18/2023Stifel NicolausBoost TargetBuy ➝ Buy$23.00 ➝ $27.00
12/11/2023GuggenheimInitiated CoverageBuy$44.00
12/11/2023Jefferies Financial GroupInitiated CoverageBuy$31.00
12/4/2023Lifesci CapitalReiterated RatingOutperform
11/29/2023TD CowenInitiated CoverageOutperform
(Data available from 6/18/2021 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2025
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2025
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 5 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026
  • 6 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2026
  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2026
  • 6 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2026

Current Sentiment

  • 6 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Spyre Therapeutics logo
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $87.49
Low: $83.17
High: $88.03

50 Day Range

MA: $71.74
Low: $51.20
High: $87.49

52 Week Range

Now: $87.49
Low: $14.00
High: $88.03

Volume

1,514,033 shs

Average Volume

966,385 shs

Market Capitalization

$7.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Spyre Therapeutics?

The following sell-side analysts have issued reports on Spyre Therapeutics in the last twelve months: BTIG Research, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., JonesTrading, Leerink Partners, Mizuho, Raymond James Financial, Inc., Robert W. Baird, Stifel Nicolaus, Wall Street Zen, Wedbush, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for SYRE.

What is the current price target for Spyre Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Spyre Therapeutics in the last year. Their average twelve-month price target is $94.17, suggesting a possible upside of 7.6%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting SYRE will reach $115.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $53.00 for Spyre Therapeutics in the next year.
View the latest price targets for SYRE.

What is the current consensus analyst rating for Spyre Therapeutics?

Spyre Therapeutics currently has 1 sell rating, 10 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SYRE will outperform the market and that investors should add to their positions of Spyre Therapeutics.
View the latest ratings for SYRE.

What other companies compete with Spyre Therapeutics?

Other companies that are similar to Spyre Therapeutics include BeOne Medicines, BioNTech, Moderna, Roivant Sciences and Insmed. Learn More about companies similar to Spyre Therapeutics.

How do I contact Spyre Therapeutics' investor relations team?

Spyre Therapeutics' physical mailing address is 805 Las Cimas Parkway, Suite 100, Austin, TX 78746, United States. The company's listed phone number is 512-942-2935 and its investor relations email address is [email protected]. The official website for Spyre Therapeutics is www.aeglea.com. Learn More about contacing Spyre Therapeutics investor relations.